NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Mereo BioPharma Group plc (NASDAQ: MREO). Shareholders who purchased shares of MREO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/mereo-biopharma-group-plc-loss-submission-form-5/?id=184862&from=3 CLAS ...

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc, alleging that the company made misleading statements regarding its Phase 3 ORBIT and COSMIC programs, which failed to meet their primary endpoints [1][1][1] Summary by Relevant Sections Allegations - The complaint claims that Mereo BioPharma provided overly positive statements to investors while concealing material adverse facts about the Phase 3 ORBIT and COSMIC programs [1][1] - Neither the ORBIT nor the COSMIC studies achieved statistical significance in reducing the annualized clinical fracture rate compared to placebo or bisphosphonate control groups [1][1] Financial Impact - Following the announcement on December 29, 2025, that the studies did not meet their primary endpoints, Mereo's American Depositary Shares (ADS) price plummeted from $2.31 per share on December 26, 2025, to $0.29 per share on December 29, 2025, marking a decline of over 87.7% [1][1][1] Class Action Details - The class period for the lawsuit is defined as June 5, 2023, to December 26, 2025, with a deadline of April 6, 2026, for shareholders to register for participation [1][1] - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [1][1]

Core Viewpoint - Mereo BioPharma Group plc is facing a class action lawsuit due to allegations of misleading statements regarding the Phase 3 ORBIT and COSMIC programs, which failed to meet their primary endpoints, leading to a significant drop in stock price [3]. Group 1: Allegations and Impact - The class period for the lawsuit is from June 5, 2023, to December 26, 2025 [3]. - Defendants allegedly provided overly positive statements while concealing adverse facts about the Phase 3 ORBIT and COSMIC programs, which did not achieve statistical significance in reducing annualized clinical fracture rates [3]. - Following the announcement on December 29, 2025, that neither study met its primary endpoint, Mereo's ADS price plummeted from $2.31 to $0.29, a decline of over 87.7% [3]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by April 6, 2026, to participate in potential recovery [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [4]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [5].

Core Viewpoint - Mereo BioPharma Group plc is facing a class action lawsuit for securities law violations due to misleading statements regarding its Phase 3 clinical trials, which did not meet their primary endpoints, leading to a significant drop in stock price [1]. Summary by Relevant Sections Allegations - The lawsuit alleges that Mereo BioPharma provided overly positive statements while concealing material adverse facts about the Phase 3 ORBIT and COSMIC programs, which failed to achieve their primary endpoints of reducing annualized clinical fracture rates compared to placebo or bisphosphonate control groups [1]. - On December 29, 2025, Mereo announced that neither the ORBIT nor the COSMIC studies achieved statistical significance, despite improvements in bone mineral density [1]. Stock Price Impact - Following the announcement of the failed clinical trials, Mereo's American Depositary Shares (ADS) price plummeted from $2.31 per share on December 26, 2025, to $0.29 per share on December 29, 2025, marking a decline of over 87.7% [1]. Class Action Details - Shareholders who purchased Mereo shares during the class period from June 5, 2023, to December 26, 2025, are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment, with a deadline set for April 6, 2026 [1]. - Participation in the class action does not require appointment as lead plaintiff, and there is no cost or obligation for shareholders to register [1].

Core Viewpoint - Mereo BioPharma Group plc is facing a class action lawsuit due to misleading statements regarding the Phase 3 ORBIT and COSMIC programs, which failed to meet their primary endpoints, leading to a significant decline in stock price [1][3]. Group 1: Class Action Details - The class action is on behalf of investors who purchased Mereo securities between June 5, 2023, and December 26, 2025, with a deadline for filing a lead plaintiff motion set for April 6, 2026 [1]. - Investors are encouraged to contact the Portnoy Law Firm for legal rights discussions and case evaluations [2]. Group 2: Program Failures - The complaint alleges that Mereo provided overly positive statements while concealing adverse facts about the Phase 3 ORBIT and COSMIC programs, which did not achieve their primary endpoints of reducing annualized clinical fracture rates [3]. - On December 29, 2025, Mereo announced that neither the ORBIT nor COSMIC studies achieved statistical significance, despite improvements in bone mineral density [3]. Group 3: Stock Price Impact - Following the announcement of the failed studies, Mereo's American Depositary Shares (ADS) price plummeted from $2.31 per share on December 26, 2025, to $0.29 per share on December 29, 2025, marking a decline of over 87.7% [3].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of American Depositary Shares of Mereo BioPharma Group plc, covering the period from June 5, 2023, to December 26, 2025, due to alleged misleading statements regarding the company's clinical programs [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Mereo BioPharma made false and/or misleading statements and concealed material adverse facts about the Phase 3 ORBIT and COSMIC programs, which did not meet their primary endpoints of reducing annualized clinical fracture rates compared to control groups [5]. - Investors who purchased Mereo securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must file a motion with the court by April 6, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc for alleged violations of securities laws, specifically related to misleading statements about its clinical programs [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from June 5, 2023, to December 26, 2025, with a deadline for lead plaintiff appointments set for April 6, 2026 [2]. - The complaint alleges that Mereo made false and misleading statements regarding its Phase 3 ORBIT and COSMIC programs, which did not meet their endpoints compared to placebo or bisphosphonate control groups [2]. Group 2: Investor Participation - Shareholders who purchased MREO shares during the class period are encouraged to contact the law firm for potential lead plaintiff appointments, although this is not necessary to participate in any recovery [2][3].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of American Depositary Shares of Mereo BioPharma Group plc, covering the period from June 5, 2023, to December 26, 2025, due to alleged misleading statements regarding the company's clinical programs [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Mereo BioPharma Group made false and/or misleading statements about the Phase 3 ORBIT and COSMIC programs, which did not meet their primary endpoints of reducing annualized clinical fracture rates compared to control groups [5]. - Investors who purchased Mereo BioPharma Group securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly. The deadline to serve as lead plaintiff is April 6, 2026 [3][6]. - It is noted that no class has been certified yet, and investors are not represented by counsel unless they retain one [7].

Core Viewpoint - A securities class action lawsuit has been filed against Mereo BioPharma Group plc for allegedly providing misleading statements regarding the Phase 3 ORBIT and COSMIC programs, which did not meet their primary endpoints [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals or entities that purchased Mereo securities between June 5, 2023, and December 26, 2025 [1]. - The Complaint claims that Mereo's misleading statements led to shareholders purchasing its American Depositary Shares (ADS) at artificially inflated prices [2]. Group 2: Study Results - The Complaint alleges that the Phase 3 ORBIT and COSMIC studies failed to achieve statistical significance in reducing the annualized clinical fracture rate compared to placebo or bisphosphonate control groups [2][3]. - Despite improvements in bone mineral density, neither study met its primary endpoint [3]. Group 3: Market Reaction - Following the announcement on December 29, 2025, that the studies did not meet their primary endpoints, Mereo's ADS price plummeted from $2.31 per share on December 26, 2025, to $0.29 per share on December 29, 2025, representing a decline of over 87.7% [4].

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc due to misleading statements regarding the Phase 3 ORBIT and COSMIC programs, which failed to meet their primary endpoints [1][2]. Group 1: Lawsuit Details - The lawsuit, Megan Dodge v. Mereo BioPharma Group plc, was initiated in the United States District Court for the Southern District of New York for investors who purchased American Depositary Shares (ADS) between June 5, 2023, and December 26, 2025 [1]. - Investors are encouraged to participate in the lawsuit before the April 6, 2026 deadline to potentially recover losses [5]. Group 2: Study Results - Mereo announced on December 29, 2025, that neither the ORBIT nor the COSMIC Phase 3 studies achieved statistical significance, failing to meet the primary endpoint of reducing annualized clinical fracture rates compared to placebo or bisphosphonates [3]. - Despite improvements in bone mineral density, the studies did not yield the expected results, leading to significant investor concerns [2][3]. Group 3: Market Reaction - Following the announcement of the study results, Mereo's ADS price plummeted from $2.31 per share on December 26, 2025, to $0.29 per share on December 29, 2025, marking a decline of over 87.7% [4].